Catalyst
Monitor results regarding feasibility and patient tolerance, as well as any subsequent studies that may arise from this trial.
Date
June 29, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.